Top in hem/onc: HPV vaccination, nivolumab

A recent study showed that quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer. It was the top story in hematology/oncology last week.

Another top story was about the potential role of the PD-1 inhibitor nivolumab (Opdivo, Bristol Myers Squibb) as the “new standard of care” for patients with esophageal and gastroesophageal junction cancers.

Read these and more top stories in hematology/oncology below:

HPV vaccination substantially reduces risk for invasive cervical cancer

Quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer among Swedish girls and women aged 10 to 30 years, according to results of a study published in The New England Journal of Medicine. Read more.

Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers

Adjuvant nivolumab significantly prolonged disease-free survival compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020. Read more.

Sharp declines in new cancer diagnoses observed during COVID-19 pandemic

The number of newly identified patients with six common types of cancer declined significantly soon after the COVID-19 pandemic began, according to data in a research letter published in JAMA Network Open. Read more.

COVID-19 antibodies in convalescent plasma donations wane by 3 to 4 months

COVID-19 antibodies in convalescent plasma began to disappear in donations made 3 to 4 months after symptom onset, according to results of a longitudinal analysis published in Blood. Read more.

Overcoming Imposter Phenomenon with Darilyn Moyer, MD

In this episode of Oncology Overdrive, Darilyn Moyer, MD, FACP, FRCP, FIDSA, executive vice president and chief executive officer of ACP, shares how she overcame imposter syndrome to advance her career in medicine. Read more.